The role of fibronectin in multiple sclerosis and the effect of drug delivery across the blood-brain barrier
Shuang-Shuang Wei1
Le Chen1
Feng-Yuan Yang1
Si-Qi Wang1
Peng Wang2
1.Ningxia Key Laboratory of Craniocerebral Diseases,School of Clinical Medicine,Ningxia Medical University,Yinchuan,Ningxia Hui Autonomous Region,China2.Ningxia Key Laboratory of Craniocerebral Diseases,Ningxia Medical University,Yinchuan,Ningxia Hui Autonomous Region,China
摘要：Remyelination failure is one of the main characteristics of multiple sclerosis and is potentially correlated with disease progression. Previous research has shown that the extracellular matrix is associated with remyelination failure because remodeling of the matrix often fails in both chronic and progressive multiple sclerosis. Fibronectin aggregates are assembled and persistently exist in chronic multiple sclerosis, thus inhibiting remyelination. Although many advances have been made in the mechanisms and treatment of multiple sclerosis, it remains very difficult for drugs to reach pathological brain tissues; this is due to the complexity of brain structure and function, especially the existence of the blood-brain barrier. Therefore, herein, we review the effects of fibronectin aggregates on multiple sclerosis and the efficacy of different forms of drug delivery across the blood-brain barrier in the treatment of this disease.
机标关键词：fibronectinbarrierroleacrossblood-braindeliverydrugeffect
论文发表日期：2023-10-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：9( 2147-2155 )
英文信息